Solutions
Our Products
iCheck IDA

Transforming iron deficiency diagnostics from acute to preventive

iCheck ID.A is an innovative device designed for the pointof-care screening of iron deficiency and associated anemia.

iCheck ID.A simultaneously measures zinc protoporphyrin and hemoglobin (Hb) in a drop of blood without any chemicals or sample processing.

Zinc protoporphyrin (ZnPP) is an established iron deficiency marker, while hemoglobin is the most used parameter in diagnosing anemia.

Request more information
iCheck ID.A

Iron deficiency and anemia persist due to suboptimal diagnostics

Anemia
  • Diagnosing anemia and its cause is a complex pathway, with generic point of care tests that require multiple laboratory follow-up tests in plasma to identify the cause.
  • Iron deficiency without anemia cannot be detected at point-of-care and therefore often remains undiagnosed, leading to blanket ineffective treatment, low clinical visibility, and low preventive screening.
1.74 billion people suffering from anemia
€43 billion in GDP losses each year

Anemia affects one in four people globally

Iron deficiency is the cause of 50% anemia cases globally
Iron deficiency develops before anemia and is 2x as prevalent as anemia
It doubles risk of maternal and perinatal death for 32 million pregnant women globally, causing 700,000 deaths
It causes 2x to 3x increased risk of mortality during or after surgery for over 230 million major surgeries globally, leading to 500,000 deaths per year

iCheck ID.A prototypes have demonstrated clinical utility in the field

2020
  • Internal feasibility study demonstrated that laboratory-prototype delivers comparable measurement of Hb and ZnPP in whole blood samples to HemoControl (EKF Diagnostics) for Hb, and to HPLC for ZnPP.
iCheck ID.A
2021 - 2022
  • Field and laboratory trials with functional prototypes demonstrated clinical utility in differentiating ID with and without anemia at point of care in finger prick blood.
iCheck ID.A
  • Development of iCheck ID.A proves to be highly anticipated innovation as confirmed by over 20 letters of interest and support from major stakeholders including WHO.
  • iCheck ID.A wins a prestigious and highly competitive Seal of Excellence during EIC Accelerator under Horizon Europe.
Learn More
2023 - 2026
  • BioAnalyt is now in the process of developing a technical prototype that meets EU IVDR requirements enabling robust, reproducible, and clinically reliable ID/IDA diagnosis.
  • This prototype integrates a multi-modal sensing approach combining multiplexed spectral analysis of fluorometric and absorption information. A machine learning based algorithm is applied, providing advanced in-depth analysis of background and sample information. The combination of these technological modalities enables further metabolic and inflammatory parameters to be targeted.
iCheck ID.A

We welcome partners and investors to speed up the delivery of our innovation to the market

iCheck ID.A

  • Early & accessible diagnosis
  • 1 step
  • 1 minute
  • <2€
  • Prevention-focused healthcare
  • Safer pregnancies & surgeries
  • Reduced costs for NHS
Women‘s Health

213M

pregnancies

Hospitals

273M

elective surgeries

Blood Donation

118M

donations

3 billion tests per year

Advisory board

Valarie Soulier

Valerie Soulier

Marketing Strategy
Prof. Dr. P. Meybohm

Prof. Dr. P. Meybohm

Surgery&Hospitals
Dr. A. Raabe

Dr. A. Raabe

Business Models
Dr. M. Stefanovic

Dr. M. Stefanovic

Financing
Dipl.-Ing. F. von Kuenheim

Dipl.-Ing. F. von Kuenheim

Investment
Dr. R. Lange

Dr. R. Lange

IVD Market